Microbot Medical Inc (NASDAQ:MBOT) rose 9.5% on Monday . The stock traded as high as $5.94 and last traded at $5.64, approximately 158,148 shares traded hands during trading. A decline of 72% from the average daily volume of 566,484 shares. The stock had previously closed at $5.15.
A number of research firms have recently issued reports on MBOT. ValuEngine cut shares of Microbot Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, December 3rd. Zacks Investment Research downgraded Microbot Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Microbot Medical in a research note on Friday, November 22nd.
The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $4.97 and a two-hundred day moving average price of $5.47. The company has a market capitalization of $22.69 million, a price-to-earnings ratio of -2.34 and a beta of 4.99.
Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). On average, sell-side analysts anticipate that Microbot Medical Inc will post -1.38 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MBOT. Morgan Stanley lifted its stake in shares of Microbot Medical by 77.0% in the second quarter. Morgan Stanley now owns 6,316 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 2,748 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Microbot Medical during the second quarter valued at about $45,000. BlackRock Inc. increased its position in shares of Microbot Medical by 5.7% during the second quarter. BlackRock Inc. now owns 183,520 shares of the biotechnology company’s stock worth $945,000 after acquiring an additional 9,906 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Microbot Medical by 5.5% during the second quarter. Renaissance Technologies LLC now owns 206,887 shares of the biotechnology company’s stock worth $1,065,000 after acquiring an additional 10,838 shares in the last quarter. Hedge funds and other institutional investors own 14.27% of the company’s stock.
Microbot Medical Company Profile (NASDAQ:MBOT)
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Featured Story: Which market index is the best?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.